

Requested

O'Hara, Eileen

From: Angela Parsons [parsons@fr.com]
Sent: Friday, February 18, 2005 11:50 AM
To: O'Hara, Eileen
Subject: U.S. Application No. 09/970,532

Examiner O'Hara,

As we discussed this morning, please find attached a document showing your proposed claim amendments for the indicated application. Applicants agree to the amendments shown on the attached document, and request that you enter them into the file as Examiner's amendments. You indicated that entry of these amendments will result in a Notice of Allowance.

Please contact me if you have any questions or any problems opening the attached document. Please also confirm receipt of this e-mail and attachment.

Thank you.

Angela

M. Angela Parsons, Ph.D.

~ Fish & Richardson P.C., P.A.

3300 Dain Rauscher Plaza

60 South Sixth Street

Minneapolis, Minnesota 55402

www.fr.com

tel (612) 337-2577

fax (612) 288-9696

parsons@fr.com

This e-mail message is intended for the sole use of the intended recipient(s) and may contain information that is confidential, privileged and/or attorneys' work product. Any review or distribution by any other person is prohibited. If you are not an intended recipient, please immediately contact the sender and delete all copies.

EXAMINER'S PROPOSED AMENDMENTS

29. (Currently Amended) A purified bovine TNF-RI polypeptide that binds bovine TNF, wherein said polypeptide is encoded by a nucleic acid selected from the group consisting of:

- (a) the nucleotide sequence of SEQ ID NO.:1;
- (b) a fragment of the nucleotide sequence of (a); and
- (c) a nucleotide sequence that is at least 85% identical to (a) or (b).

30. (Currently Amended) A purified soluble bovine TNF-RI polypeptide that binds bovine TNF, wherein said polypeptide is encoded by a nucleic acid selected from the group consisting of :

- (a) the nucleotide sequence of SEQ ID NO.:3,
- (b) a fragment of the nucleotide sequence of (a); and
- (c) a nucleotide sequence that is at least 85% identical to (a) or (b).

31. (Currently Amended) The polypeptide of claim 30, wherein said polypeptide comprises a bovine TNF-RI extracellular domain or a fragment ~~fragments~~ thereof.

32. (Currently Amended) A purified bovine TNF-RI polypeptide, wherein said polypeptide is selected from the group consisting of:

- (a) the polypeptide of SEQ ID NO:2; and
- (b) a fragment of the polypeptide of (a) that binds bovine TNF.

33. (Currently Amended) A purified soluble bovine TNF-RI polypeptide, wherein said polypeptide is selected from the group consisting of:

- (a) the polypeptide of SEQ ID NO:4; and
- (b) a fragment of the polypeptide of (a) that binds bovine TNF.

34. (Currently Amended) The polypeptide of claim 33, wherein said polypeptide comprises a bovine TNF-RI extracellular domain or a fragment ~~fragments~~ thereof.

35. (Previously Presented) The polypeptide of claim 29, wherein said nucleotide sequence is at least 90% identical to (a) or (b).

36. (Previously Presented) The polypeptide of claim 29, wherein said nucleotide sequence is at least 95% identical to (a) or (b).

37. (Previously Presented) The polypeptide of claim 30, wherein said nucleotide sequence is at least 90% identical to (a) or (b).

38. (Previously Presented) The polypeptide of claim 30, wherein said nucleotide sequence is at least 95% identical to (a) or (b).

39. (Currently Amended) The polypeptide of claim 29, wherein said polypeptide comprises a bovine TNF-RI extracellular domain or a fragment ~~fragments~~ thereof.

40. (Currently Amended) The polypeptide of claim 32, wherein said polypeptide comprises a bovine TNF-RI extracellular domain or a fragment ~~fragments~~ thereof.

41-58. (Canceled)

59. (Previously Presented) The polypeptide of claim 29, wherein said polypeptide is purified to greater than 95% purity.

60. (Previously Presented) The polypeptide of claim 30, wherein said polypeptide is purified to greater than 95% purity.

61. (Previously Presented) The polypeptide of claim 32, wherein said polypeptide is purified to greater than 95% purity.

62. (Previously Presented) The polypeptide of claim 33, wherein said polypeptide is purified to greater than 95% purity.